The United States and United Kingdom Conclude Duty-Free Pact on Drugs.

The UK and US have reached a significant trade agreement that will keep zero levies on British pharmaceutical shipments going into the US market.

Key Provisions of the Deal

In exchange for the tariff guarantee, the UK has committed to raise funding on drugs through the NHS. This pledge secures that duties on these crucial products will be held at zero for a period of the next three years.

This development comes after recent statements to hike import taxes on branded drug products, with increases mentioned reaching double the cost.

"This deal with the United Kingdom strengthens the global environment for innovative medicines and brings much-needed equity to transatlantic medicine commerce," a statement noted.

Trade Significance

Drugs constitute one of the the United Kingdom's largest goods shipped to the United States, which is by far the largest market for large companies like GSK and AstraZeneca.

Statistics indicate that in the 12 months prior to the third quarter, the UK shipped drugs totaling £11.1bn to the US. This amount made up a significant portion of all goods exports in that timeframe.

"This guarantee protects jobs, increases funding and sets the stage for the UK to establish itself as a global hub for medical research," a government official commented.

Specific NHS Changes

The agreement includes several notable commitments from the United Kingdom:

• Higher Cost Ceiling: The UK will lift the affordability limit at which it deems new treatments to be too expensive by twenty-five percent.
• Higher Drug Budget: There is a target to raise overall public funding on treatments from 0.3% of Gross Domestic Product to 0.6% over the following ten-year period.
• Rebate Cap: The percentage drug companies must refund to the NHS to control costs will be capped at 15%. In the past, rebates exceeded 20%.

Industry Background

This agreement follows a ongoing row between the drug companies and the UK government over medicine costs and approval rates.

The disagreement were heightened by claims that US customers were paying several times more for the same drugs than patients in the Britain and the EU.

In recent months, several major drug company projects in the UK have been halted or cancelled, while major funding commitments have been announced toward projects in the United States.

One official publicly accepted that the NHS needed to invest a greater share on drugs, noting that its budget allocation on drugs had decreased as a percentage of its resources over the previous ten-year period.